Media Thread, page-15731

I finally watched the presentation and noticed something that hasn’t been mentioned by anyone, YF indicated there are anti-CD19 MABS in development. So, if onCARlytics proves successful, IMU’s B Cell platform could be used to develop an anti-CD19 vaccine to partner with onCARlytics.

However, it is probably not suitable to create an anti-CD19 B Cell vaccination as it would be long lasting and its side effects would likely lead to non-cancerous B Cells being killed. So, they would most likely need to wait for a second generation onCARlytics to be developed that creates an alternate target for which a B Cell platform drug could be tailored.

What’s the potential relevance or benefit over using a CAR-T? I think they would still use a CAR-T for the initial rounds of treatment as it appears the CAR-Ts help spread the virus quicker however CAR-Ts may not persist in the body as long as onCARlytics so if a patient received a B Cell platform vaccination at the same time, the body would produce a drug needed to work in combination with onCARlytics and perhaps could receive subsequent onCARlytics treatments without needing the accompanying CAR-T treatment. The catch might be that the B Cell platform might not generate an antibody response due to the anti CD19 CAR-T so, might be something for the next generation of onCARlytics which would be designed to have a different target site the CAR-T and B Cell platform drugs could target. So, there may be additional value from the B Cell platform on a much larger scale that what has previously existed.